Analysts Revise Argenx Revenue Forecasts Upward, Signaling Stronger Growth Trajectory
Recent analyst reports from Wells Fargo and H.C. Wainwright suggest consensus revenue estimates for biotech firm Argenx SE may be too conservative, with key drug Vyvgart poised to outperform expectations through 2030.